Search

Displaying results 1981 - 1990 of 10000 in total
  1. Drug

    Riluzole

    go.drugbank.com/drugs/DB00740
    ApprovedInvestigational

    A glutamate antagonist (receptors, glutamate) used as an anticonvulsant (anticonvulsants) and to prolong the survival of patients with amyotrophic lateral sclerosis.

    Categories: Compounds used in a research, industrial, or household setting
  2. Drug

    Anthrax vaccine

    go.drugbank.com/drugs/DB11003
    ApprovedInvestigational

    [L47566, L47561] These vaccines are currently stored in the Strategic National Stockpile in preparation for an Anthrax terrorist attack or for pre-exposure prophylaxis of personnel going to specific arenas … [L47561] There are currently 2 anthrax vaccines approved by the FDA: BioThrax in August 15, 2016 and CYFENDUS in July 20, 2023.

  3. Drug

    Plicamycin

    go.drugbank.com/drugs/DB06810
    ApprovedWithdrawn

    Plicamycin is an antineoplastic antibiotic produced by Streptomyces plicatus. … It has been used in the treatment of testicular cancer, Paget's disease of bone, and, rarely, the management of hypercalcemia. The manufacturer discontinued plicamycin in 2000.

    Categories: Compounds used in a research, industrial, or household setting
  4. Drug

    Rolapitant

    go.drugbank.com/drugs/DB09291
    ApprovedInvestigational

    By blocking Substance P from interacting with NK-1 receptors in the gut and the central nervous system, rolapitant prevents late-phase CINV. … Rolapitant is a potent, highly selective, long-acting Neurokinin-1 (NK-1) receptor antagonist approved for the prevention of delayed chemotherapy-induced nausea and vomiting (CINV) in adults.

  5. Drug

    Carprofen

    go.drugbank.com/drugs/DB00821
    ApprovedVet approvedWithdrawn

    Carprofen was previously used in human medicine for over 10 years (1985-1995). … It is no longer marketed for human usage, after being withdrawn on commercial grounds.

  6. Drug

    Lunsotogene parvec

    go.drugbank.com/drugs/DB18278
    ApprovedInvestigational

    Lunsotogene parvec is a first-in-class dual adeno-associated virus serotype 1 vector-based gene therapy developed to address an unmet medical need for OTOF-related sensorineural hearing loss. … [L56137] It acts by delivering functional copies of the human _OTOF_ gene specifically to inner hair cells via an engineered hair-cell-specific Myo15 promoter, which restores essential synaptic transmission

  7. Drug

    Succinic acid

    go.drugbank.com/drugs/DB00139
    ApprovedInvestigationalNutraceutical

    (Hawley's Condensed Chemical Dictionary, 12th ed, p1099; McGraw-Hill Dictionary of Scientific and Technical Terms, 4th ed, p1851) … A water-soluble, colorless crystal with an acid taste that is used as a chemical intermediate, in medicine, the manufacture of lacquers, and to make perfume esters.

  8. Drug

    Abametapir

    go.drugbank.com/drugs/DB11932
    Approved

    [A216178] Abametapir was first approved for use in the United States under the brand name Xeglyze on July 27, 2020.[L15163] … [A216178] Abemetapir is an inhibitor of these metalloproteinase enzymes, and the first topical pediculicide to take advantage of this novel target.

  9. Drug

    Artenimol

    go.drugbank.com/drugs/DB11638
    ApprovedInvestigational

    Artenimol is an artemisinin derivative and antimalarial agent used in the treatment of uncomplicated *Plasmodium falciparum* infections [FDA Label]. … It was first authorized for market by the European Medicines Agency in October 2011 in combination with [DB13941] as the product Eurartesim.

  10. Drug

    Technetium Tc-99m oxidronate

    go.drugbank.com/drugs/DB09139
    ApprovedWithdrawn

    [L1137] The radiopharmaceuticals based on technetium-99m are widely used for diagnostic purposes because 99mTc has a versatile chemistry which allows it to produce an extense variety of complexes with … [L1140] It was developed by Mallinkrodt nuclear and FDA approved on February 18, 1981.